(DIM) Sartorius Stedim Biotech - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: PA (France) | Market Cap: 16.605m EUR | Total Return: -11% in 12m
Avg Turnover: 14.1M
EPS Trend: -31.9%
Qual. Beats: 0
Rev. Trend: 6.4%
Qual. Beats: 0
Warnings
Choppy
Tailwinds
No distinct edge detected
Sartorius Stedim Biotech S.A. (DIM) is a France-based provider of equipment and consumables for the biopharmaceutical industry. The company supports the entire drug manufacturing value chain, offering solutions for cell line development, fermentation, purification, and fluid management. Its portfolio includes bioreactors, cell culture media, and advanced data analytics software used by pharmaceutical manufacturers and research laboratories globally.
The company operates within the bioprocessing sector, a specialized niche of the life sciences industry characterized by high barriers to entry and a recurring revenue model driven by single-use consumables. Unlike traditional hardware manufacturers, bioprocessing firms benefit from lock-in effects, as their technologies are often integrated into the regulatory filings of standardized drug production processes.
A detailed analysis of the companys valuation metrics and historical performance is available on ValueRay for further investigation. Sartorius Stedim Biotech remains a subsidiary of the German-listed Sartorius AG, maintaining a focused presence on large-scale biological production and laboratory automation.
- Bioprocessing inventory destocking cycles pressure short-term consumable revenue growth
- Increasing demand for monoclonal antibodies and cell therapies boosts bioreactor sales
- High capital expenditure by biopharma clients dictates long-term equipment order books
- European energy costs and supply chain volatility impact manufacturing profit margins
- Expansion into emerging markets like Sub-Saharan Africa diversifies geographic revenue streams
| Net Income: 268.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.43 > 1.0 |
| NWC/Revenue: 1.39% < 20% (prev 28.53%; Δ -27.14% < -1%) |
| CFO/TA 0.07 > 3% & CFO 610.5m > Net Income 268.1m |
| Net Debt (2.27b) to EBITDA (842.7m): 2.69 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.3m) vs 12m ago 0.02% < -2% |
| Gross Margin: 44.71% > 18% (prev 0.44%; Δ 4.43k% > 0.5%) |
| Asset Turnover: 36.19% > 50% (prev 34.42%; Δ 1.77% > 0%) |
| Interest Coverage Ratio: 2.96 > 6 (EBITDA TTM 842.7m / Interest Expense TTM 175.8m) |
| A: 0.01 (Total Current Assets 1.65b - Total Current Liabilities 1.61b) / Total Assets 8.19b |
| B: 0.33 (Retained Earnings 2.66b / Total Assets 8.19b) |
| C: 0.06 (EBIT TTM 520.9m / Avg Total Assets 8.25b) |
| D: 1.02 (Book Value of Equity 4.11b / Total Liabilities 4.05b) |
| Altman-Z'' = 2.58 = A |
| DSRI: 1.09 (Receivables 302.8m/267.0m, Revenue 2.98b/2.86b) |
| GMI: 0.98 (GM 44.71% / 43.89%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 1.04 (Revenue 2.98b / 2.86b) |
| TATA: -0.04 (NI 268.1m - CFO 610.5m) / TA 8.19b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at EUR 171.70 with a total of 69,180 shares traded.
Over the past week, the price has changed by +6.38%,
over one month by +7.51%,
over three months by -5.28% and
over the past year by -10.97%.
Sartorius Stedim Biotech has no consensus analysts rating.
P/E Trailing = 61.6246
P/E Forward = 34.7222
P/S = 5.564
P/B = 4.0418
P/EG = 1.4426
Revenue TTM = 2.98b EUR
EBIT TTM = 520.9m EUR
EBITDA TTM = 842.7m EUR
Long Term Debt = 1.86b EUR (from longTermDebt, last quarter)
Short Term Debt = 605.7m EUR (from shortTermDebt, last quarter)
Debt = 2.79b EUR (from shortLongTermDebtTotal, last quarter) + Leases 172.4m
Net Debt = 2.27b EUR (calculated: Debt 2.79b - CCE 521.2m)
Enterprise Value = 18.9b EUR (16.6b + Debt 2.79b - CCE 521.2m)
Interest Coverage Ratio = 2.96 (Ebit TTM 520.9m / Interest Expense TTM 175.8m)
EV/FCF = 88.60x (Enterprise Value 18.9b / FCF TTM 213.0m)
FCF Yield = 1.13% (FCF TTM 213.0m / Enterprise Value 18.9b)
FCF Margin = 7.14% (FCF TTM 213.0m / Revenue TTM 2.98b)
Net Margin = 8.98% (Net Income TTM 268.1m / Revenue TTM 2.98b)
Gross Margin = 44.71% ((Revenue TTM 2.98b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 45.36% (prev 41.04%)
Tobins Q-Ratio = 2.30 (Enterprise Value 18.9b / Total Assets 8.19b)
Interest Expense / Debt = 6.31% (Interest Expense 175.8m / Debt 2.79b)
Taxrate = 26.03% (31.0m / 119.1m)
NOPAT = 385.3m (EBIT 520.9m * (1 - 26.03%))
Current Ratio = 1.03 (Total Current Assets 1.65b / Total Current Liabilities 1.61b)
Debt / Equity = 0.68 (Debt 2.79b / totalStockholderEquity, last quarter 4.11b)
Debt / EBITDA = 2.69 (Net Debt 2.27b / EBITDA 842.7m)
Debt / FCF = 10.64 (Net Debt 2.27b / FCF TTM 213.0m)
Total Stockholder Equity = 4.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.25% (Net Income 268.1m / Total Assets 8.19b)
RoE = 6.60% (Net Income TTM 268.1m / Total Stockholder Equity 4.06b)
RoCE = 8.80% (EBIT 520.9m / Capital Employed (Equity 4.06b + L.T.Debt 1.86b))
RoIC = 5.36% (NOPAT 385.3m / Invested Capital 7.19b)
WACC = 7.13% (E(16.6b)/V(19.4b) * Re(7.54%) + D(2.79b)/V(19.4b) * Rd(6.31%) * (1-Tc(0.26)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 31.46 | Cagr: 2.44%
[DCF] Terminal Value 73.10% ; FCFF base≈361.2m ; Y1≈316.8m ; Y5≈255.9m
[DCF] Fair Price = 18.94 (EV 4.11b - Net Debt 2.27b = Equity 1.84b / Shares 97.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -31.94 | EPS CAGR: -7.44% | SUE: -0.28 | # QB: 0
Revenue Correlation: 6.44 | Revenue CAGR: 0.33% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=-6.24% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.22 | Chg30d=-1.20% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=5.04 | Chg30d=-2.62% | Revisions=-8% | GrowthEPS=+14.6% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=6.05 | Chg30d=-2.18% | Revisions=-29% | GrowthEPS=+20.0% | GrowthRev=+10.5%
[Analyst] Revisions Ratio: -29%